Zolgensma 20000000000000 Vg (Onasemnogene Abeparvovec SOLUTION) 20000000000000 VG

Zolgensma is a gene therapy used to treat spinal muscular atrophy (SMA), a genetic disorder affecting motor neurons in the spinal cord.

• Spinal muscular atrophy (SMA) type 1: Zolgensma provides a functional copy of the SMN1 gene, which is essential for the production of the SMN protein, crucial for the survival of motor neurons.
• Pediatric patients less than 2 years of age: Zolgensma is indicated for use in pediatric patients under 2 years old with SMA and bi-allelic mutations in the SMN1 gene.
• Motor neuron survival: By delivering the SMN1 gene, Zolgensma helps in the production of the SMN protein, which is deficient in SMA patients.

• Zolgensma works by delivering a functional copy of the SMN1 gene via an adeno-associated virus serotype 9 (AAV9) vector. This gene therapy results in increased production of the survival motor neuron (SMN) protein, which is crucial for the survival of motor neurons. The recombinant AAV9 vector contains a transgene encoding the human SMN protein, under the control of a cytomegalovirus enhancer/chicken-β-actin hybrid promoter.

Zolgensma, like any medication, can cause side effects. It is important to be aware of these potential effects when considering treatment.

Common Side Effects

• Fever: An elevated body temperature is a common side effect.
• Vomiting: Nausea and vomiting may occur after administration.
• Liver enzyme elevation: Increased liver enzymes may be observed.
• Respiratory infections: Upper and lower respiratory infections are possible.
• Constipation: Difficulty in passing stools may be experienced.
• Elevated troponin: Increased levels of troponin, a marker of heart muscle damage, may be observed.
• Acute kidney injury: Kidney function may be temporarily affected.
• Thrombocytopenia: A decrease in platelet count may occur.
• Cardiac arrhythmias: Abnormal heart rhythms may be observed.

Serious or Rare Side Effects

• Anaphylaxis: Severe allergic reactions can occur, which may be life-threatening.
• Hepatotoxicity: Severe liver damage is a potential risk.
• Thrombotic microangiopathy: A rare but serious condition affecting blood vessels and the kidneys.

Zolgensma should be used with caution and under the supervision of a healthcare professional. Certain precautions and warnings should be considered.

• Administration by healthcare professionals: Zolgensma should only be administered by healthcare professionals experienced in the use of gene therapy products.
• Monitoring for adverse reactions: Patients should be closely monitored for signs of adverse reactions, including fever, vomiting, and liver enzyme elevation.
• Pre-existing liver disease: Patients with pre-existing liver disease should be carefully evaluated before treatment.
• Immunosuppressive therapy: The use of immunosuppressive therapy may be required to manage potential immune responses to the AAV9 vector.
• Pregnancy and breastfeeding: The safety of Zolgensma in pregnant or breastfeeding women has not been established.
• Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Zolgensma may interact with other medications, and these interactions should be carefully considered.

Major Interactions (Avoid)

• Immunosuppressive drugs: Concomitant use of immunosuppressive drugs may increase the risk of infections and other adverse effects.
• Other gene therapies: The safety and efficacy of Zolgensma in combination with other gene therapies have not been established.
• Live vaccines: The use of live vaccines should be avoided due to the potential for increased risk of infections.

Moderate Interactions (Monitor Closely)

• Anticoagulants: Close monitoring is required when using anticoagulants due to the potential for increased risk of bleeding.
• Cytotoxic drugs: The use of cytotoxic drugs should be carefully monitored due to the potential for increased risk of adverse effects.
• Immunomodulators: The use of immunomodulators should be carefully monitored due to the potential for increased risk of infections.